Multimodal antibody therapy to treat Staphylococcus aureus bloodstream infections
Official title: A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia
Funded at Abvacc, INC. · NIH-11399169 · Data updated 2026-11-12
A hospital-focused immunotherapy approach uses a mix of antibodies to help fight blood infections from Staphylococcus aureus by blocking immune evasion and bacterial growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 22, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $642,054 |
| NIH project number | 5R01AI193221-02 |
| Project ID | NIH-11399169 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with confirmed Staphylococcus aureus bacteremia or at high risk for SA bloodstream infection and who are suitable for antibody-based therapy.
✕Less likely to help
Patients with infections caused by organisms other than Staphylococcus aureus or those with conditions that preclude antibody therapy may not benefit.
What this research studies
This project aims to develop an immunotherapeutic antibody cocktail that targets Staphylococcus aureus in bacteremia by hitting key toxin factors, immune evasion proteins, and enzymes the bacteria use to divide. By combining antibodies against pore-forming toxins, protein A, and autolysin, the approach seeks to enhance immune clearance and limit bacterial growth in patients with bloodstream infections. The study will use translational models to assess how the cocktail interacts with human immune components and to optimize dosing strategies for potential clinical use. If successful, this could lead to a new therapeutic option for a dangerous infection with few current immunotherapies.
Why it matters
Potential benefit: If successful, patients with SA bacteremia could receive a new antibody treatment that helps the immune system clear the infection more effectively and speeds recovery.
How similar studies have gone: Previous work in antibody-based approaches against SA has shown promise in preclinical models, supporting further development of combination immunotherapies.
Where this research is happening
-
Abvacc, INC.
Rockville, United States Active
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Collaborative AI for safer, faster bacteremia care
A physician-centered AI system is being built to help diagnose and treat bloodstream infections more accurately and safely, with the goal of reducing sepsis deaths.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.